Alternative to Entresto in ARB-Allergic Heart Failure Patients
If a heart failure patient has an ARB allergy, you cannot use Entresto (sacubitril/valsartan) because it contains valsartan, an ARB component—instead, use an ACE inhibitor (ACEi) as the primary alternative for renin-angiotensin system blockade. 1, 2
Why Entresto Cannot Be Used
Entresto is contraindicated in patients with hypersensitivity to any component, including those with a history of angioedema related to previous ARB therapy 2. Since Entresto contains valsartan (an ARB), patients with ARB allergy cannot receive this medication due to cross-reactivity risk and the drug's composition itself 2.
Primary Alternative: ACE Inhibitors
ACE inhibitors are the guideline-recommended alternative for patients who cannot take ARBs or ARNIs 1. The 2022 AHA/ACC/HFSA guidelines explicitly state that ACEi reduce morbidity and mortality in HFrEF, with benefits established across all symptom severities 1.
Key Implementation Points:
- Start at low doses and titrate upward to target doses proven in clinical trials
- Target doses matter: Use the doses shown to reduce cardiovascular events in RCTs, not just any dose
- If maximal doses aren't tolerated, use intermediate doses rather than discontinuing—abrupt withdrawal can cause clinical deterioration 1
Critical Caveat About Angioedema:
Exercise caution even with ACE inhibitors in ARB-allergic patients. While the guidelines note that ARBs are alternatives for ACEi-induced angioedema, they specifically warn that "caution is advised" when using ARBs in patients with ACEi-induced angioedema 1. This cross-reactivity concern works both ways—if the ARB allergy involved angioedema, there is increased risk with ACE inhibitors as well. However, ACE inhibitors remain the best available option, as they work through a different mechanism (kininase inhibition) compared to ARBs.
Monitoring Requirements:
Give ACE inhibitors with caution in patients with:
- Low systemic blood pressure
- Renal insufficiency
- Elevated serum potassium (>5.0 mEq/L) 1
Why This Matters Clinically
The superiority of ARNI over ACEi has been established 1, 3, but when ARNI is contraindicated due to ARB allergy, continued use of an ACEi for all classes of HFrEF remains strongly advised 1. There is no evidence suggesting that other medication classes (beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) can substitute for renin-angiotensin system blockade—these are complementary therapies, not alternatives.
The guideline evidence is unequivocal: ACE inhibitors remain a cornerstone of HFrEF therapy when ARNIs are inappropriate 1.